Sun Pharma acquires US-based Pharmalucence
Sun Pharmaceutical Industries Ltd, India’s third-largest generic drug-maker by sales, has acquired US-based Pharmalucence Inc.
Pharmalucence has sterile injectable capacity in the US, supported by strong R&D capabilities.
Earlier this year, Sun Pharma had acquired Ranbaxy Laboratories in an all-stock transaction with a total equity value of $3.2 billion along with debt of $800 million, taking the overall deal value to $4 billion.
Sun Pharma shares were trading at Rs 748.30 in early trade on Wednesday, up 1.30 per cent from its previous close.
Source: Reuters
post_id:
uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
